|
|
Correlation of Clinical Features and
Methylation Status of MGMT Gene Promoter in Glioblastomas
J.L. Blanc, M. Wager, J. Guilhot, S. Kusy, B. Bataille,
T. Chantereau, F. Lapierre, C.J. Larsen, L. Karayan-Tapon
Laboratory
of Molecular Oncology, EA 2224, IBMIG, Poitiers, France; Department of
Neurological Surgery, Poitiers, France (J.L.B).
Department of Neurological Surgery, Poitiers, France
(M.W., B.B.). Department of Haematologic Oncology and Cellular Therapie, CHU La
Milétrie,
Poitiers, France (J.G.).
Laboratory of Human Genetic, EA 2224, IBMIG, Poitiers,
France (S.K.). Laboratory of Molecular Oncology, EA 2224, IBMIG, Poitiers,
France (T.C., C.J.L., L.K.-T.). Department of Neurological Surgery, CHU La Milétrie, Poitiers, France (F.L.).
In an effort to extend the potential relationship between the methylation
status of MGMT promoter and response to CENU therapy, we examined the
methylation status of MGMT promoter in 44 patients with glioblastomas.
Tumor specimens were obtained during surgery before adjuvant treatment, frozen
and stored at -80 °C until for DNA extraction
process.
DNA methylation patterns in the CpG island of the MGMT gene were
determined in every tumor by methylation specific PCR (MSP).
These results were then related to overall survival and response to
alkylating agents using statistical analysis.
Methylation of the MGMT promoter was detected in 68% of tumors, and 96.7%
of methylated tumors exhibited also an unmethylated status.
There was no relationship between the methylation status of the MGMT
promoter and overall survival and response to alkylating agents.
Our observations do not lead us to consider promoter methylation of MGMT
gene as a prognostic factor of responsiveness to alkylating agents in
glioblastomas.
Keywords: alkylating agents, CENU, grade IV gliomas, methylation, MGMT
Copyright
©
2004 Kluwer Academic Publishers.
All rights reserved
Source: http://ipsapp009.kluweronline.com/IPS/content/ext/x/J/5042/I/119/A/11/abstract.htm
|
